Kiumars Movassaghi
Eugene, ORNPI 1306841275
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 93.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $130,937 and has fallen 51.2% since, to $63,882 in 2025.
Across 427 payments — averaging $1095.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$435K
- Integra Lifesciences Corporation$23K
- Sientra, Inc.$4K
- Motiva USA, LLC$2K
- Surgical Innovation Associates, Inc.$2K
- Davol Inc.$1K
- plus $1K from 5 others
Across 2 payments — averaging $3875.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sientra, Inc.$8K
What the payments were for
- Consulting fees$187,41040%
- Speaking & faculty fees$231,80150%
- Travel & lodging$17,2264%
- Food & beverage$14,1583%
- Education$170%
- Gifts$16,2873%
- Other$9780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 343 | $435,164 |
| Integra Lifesciences Corporation | 20 | $23,124 |
| Sientra, Inc. | 15 | $4,123 |
| Motiva USA, LLC | 14 | $1,804 |
| Surgical Innovation Associates, Inc. | 1 | $1,500 |
| Davol Inc. | 13 | $1,131 |
| Mentor Worldwide LLC | 13 | $526 |
| Tepha Inc | 5 | $285 |
| Guard Medical Inc. | 1 | $100 |
| BD | 1 | $89 |
| Revance Therapeutics, Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NATRELLE SALINE-FILLED BREAST IMPLANTS$260,446
- NATRELLE$78,443
- ALLODERM$76,437
- REVOLVE$70,678
- STRATTICE$37,226
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS$27,245
- INTEGRA$23,271
- OMNIGRAFT$12,824
- BOTOX$10,303
- SURGIMEND$4,024
- CODMAN CERTAS$3,850
- SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT$3,671
- DuraSorb Monofilament Mesh$2,611
- Motiva Implant Matrix$1,610
- INTEGRA DERMAL REGENERATION TEMPLATE$298
- Phasix Mesh$296
- GalaFLEX$174
- Agento I.C. Silver-Coated Endotracheal Tube$146
- ARISTA AH FLEXITIP$134
- PRIMATRIX$124
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 26 | $126 |
| Oxycodone Hcl | 17 | $108 |
| ValacyclovirValacyclovir Hcl | 18 | $99 |
| Celecoxib | 12 | $70 |
| Ondansetron OdtOndansetron | 19 | $61 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.